Zacks Research Brokers Raise Earnings Estimates for Revvity

Revvity, Inc. (NYSE:RVTY) – Equities research analysts at Zacks Research upped their Q2 2025 earnings estimates for shares of Revvity in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now expects that the company will earn $1.28 per share for the quarter, up from their prior estimate of $1.27. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $5.17 EPS, Q2 2026 earnings at $1.40 EPS and FY2026 earnings at $5.67 EPS.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.15. The business had revenue of $684.10 million for the quarter, compared to the consensus estimate of $679.66 million. Revvity had a return on equity of 7.42% and a net margin of 9.34%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.18 earnings per share.

RVTY has been the topic of several other research reports. Wells Fargo & Company started coverage on shares of Revvity in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 price objective on the stock. Barclays reduced their price target on Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research note on Monday. Leerink Partners lifted their price objective on Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Sanford C. Bernstein reduced their target price on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Raymond James raised their price target on Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.73.

Revvity Price Performance

NYSE:RVTY opened at $116.23 on Thursday. Revvity has a 12-month low of $86.30 and a 12-month high of $129.50. The firm has a market cap of $14.15 billion, a price-to-earnings ratio of 56.15, a price-to-earnings-growth ratio of 2.86 and a beta of 1.05. The company’s 50-day moving average is $120.05 and its two-hundred day moving average is $115.89. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently modified their holdings of the stock. Tidal Investments LLC raised its holdings in shares of Revvity by 2,388.8% during the 3rd quarter. Tidal Investments LLC now owns 52,787 shares of the company’s stock valued at $6,744,000 after buying an additional 50,666 shares during the period. Coldstream Capital Management Inc. grew its position in Revvity by 5.1% in the third quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock valued at $286,000 after acquiring an additional 110 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Revvity by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company’s stock valued at $364,569,000 after purchasing an additional 25,078 shares during the period. Guardian Wealth Management Inc. lifted its position in shares of Revvity by 1.4% during the third quarter. Guardian Wealth Management Inc. now owns 11,796 shares of the company’s stock worth $1,507,000 after purchasing an additional 158 shares in the last quarter. Finally, Continuum Advisory LLC lifted its position in shares of Revvity by 2,972.7% during the third quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock worth $43,000 after purchasing an additional 327 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Insider Activity at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the transaction, the insider now directly owns 23,960 shares of the company’s stock, valued at $2,925,276.40. This trade represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.60% of the company’s stock.

Revvity announced that its board has initiated a stock buyback program on Monday, November 4th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 6.5% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s dividend payout ratio is presently 13.53%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.